Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
47
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Puissance Life Science Opportunities Fund VI | 10% Owner | 4 | $0 | $107.7K | 2023-10-13 |
| Kim Bobae | VP Reg. Affairs & Quality | 6 | $0 | $94.5K | 2023-06-07 |
| Teufel Crispin | Director | 6 | $0 | $0 | 2023-06-07 |
| Wang Theodore T | Director, 10% Owner | 17 | $490.1K | $0 | 2023-06-07 |
| Shah Parag Suresh | VP of Business Operations | 18 | $0 | $0 | 2023-06-07 |
| Cloyd Mary Ann | Director | 9 | $0 | $0 | 2023-06-07 |
| Puissance Capital Management LP | 10% Owner | 3 | $0 | $5.41M | 2023-06-07 |
| Amin Naseem | Director | 18 | $400.0K | $0 | 2023-06-07 |
| Dekker Martin | VP of Engineering & Manuf | 19 | $0 | $0 | 2023-06-07 |
| Fernandes Peter | See Remarks | 20 | $0 | $0 | 2023-06-07 |
| Bruder Scott P | Director | 10 | $0 | $0 | 2023-06-07 |
| Laccona Nicholas | FINANCIAL OFFICER, (PFO & PAO) | 5 | $0 | $0 | 2023-02-10 |
| Peacock Jonathan M | President and CEO | 22 | $900.1K | $0 | 2021-03-31 |
| New Mountain Capital, L.L.C. | 10% Owner | 1 | $0 | $2.19M | 2021-03-18 |
| FARES Wassim | Chief Medical Officer | 2 | $40.7K | $0 | 2020-09-10 |
| Moura Andre V. | Director | 8 | $0 | $0 | 2020-09-10 |
| BENNETT MATTHEW | Director | 4 | $0 | $0 | 2020-09-10 |
| Puissance Capital Fund (GP) LLC | 10% Owner | 1 | $0 | $0 | 2020-05-21 |
| Puissance Cross-Border Opportunities III LLC | 10% Owner | 1 | $0 | $0 | 2020-04-17 |
| Korner Assaf | CFO | 6 | $0 | $0 | 2019-11-15 |
| Tenenbaum Fabian | Chief Executive Officer | 15 | $3.0K | $0 | 2019-11-15 |
| Venrock Healthcare Capital Partners III, L.P. | 10% Owner | 6 | $558.3K | $524.1K | 2019-10-28 |
| Venrock Management IV, LLC | 10% Owner | 3 | $0 | $524.1K | 2019-10-28 |
| Edmonds Amy | VP Clinical Operations & Admin | 12 | $0 | $0 | 2019-09-26 |
| Shah Nimish P | 10% Owner | 4 | $444.1K | $0 | 2019-01-23 |
| VENROCK ASSOCIATES IV L P | 10% Owner | 1 | $100.0K | $0 | 2019-01-23 |
| VHCP Management III, LLC | 10% Owner | 3 | $252.3K | $0 | 2018-09-17 |
| Venrock Partners, L.P. | 10% Owner | 6 | $596.4K | $0 | 2018-09-17 |
| VHCP Co-Investment Holdings II, LLC | 10% Owner | 3 | $558.3K | $0 | 2018-09-12 |
| VHCP Co-Investment Holdings III, LLC | 10% Owner | 3 | $138.5K | $0 | 2018-09-07 |
| Venrock Partners Management, LLC | 10% Owner | 3 | $138.5K | $0 | 2018-09-07 |
| Luehring Jens | Director, 10% Owner | 10 | $4.32M | $0 | 2018-06-21 |
| Tasse Daniel | Director | 7 | $300.0K | $0 | 2018-06-21 |
| Quinn Deborah | Chief Medical Officer | 8 | $0 | $0 | 2018-06-12 |
| Schoeps Megan | Principal Financial Officer | 4 | $0 | $0 | 2017-12-13 |
| Weinstein Adam | Director, 10% Owner | 7 | $12.84M | $0 | 2017-09-22 |
| Holt Matthew S. | Director, 10% Owner | 5 | $12.84M | $0 | 2016-06-17 |
| Abrams David | Treasurer | 3 | $0 | $0 | 2015-12-01 |
| Agrawal Amit | Chief Operating Officer | 1 | $0 | $0 | 2015-07-08 |
| MEGLASSON MARTIN | Chief Scientific Officer | 4 | $150.0K | $0 | 2015-05-20 |
| Huennekens R Scott | Director | 1 | $0 | $0 | 2015-05-12 |
| Naidu Manesh | Chief Business Officer | 3 | $18.0K | $0 | 2015-03-12 |
| Heyrman Reinilde | Chief Clinical Dev. Officer | 3 | $18.0K | $0 | 2015-03-12 |
| Linde North America, Inc. | 10% Owner | 1 | $4.31M | $0 | 2015-02-19 |
| ARCH VENTURE PARTNERS VI LLC | 10% Owner | 1 | $2.55M | $0 | 2015-02-19 |
| NELSEN ROBERT | Director, 10% Owner | 3 | $2.55M | $0 | 2015-02-19 |
| KLINSKY STEVEN B | 10% Owner | 1 | $12.84M | $0 | 2015-02-19 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Puissance Life Science Opportu | 10% Owner | S Sale | 2023-10-13 | 2023-10-16 | 1,076,841 | $0.10 | $107.7K | 0 | SEC↗ |
| Teufel Crispin | Director | A Award deriv | 2023-06-07 | 2023-06-09 | 14,607 | — | $0 | 14,607 | SEC↗ |
| Cloyd Mary Ann | Director | A Award deriv | 2023-06-07 | 2023-06-09 | 14,607 | — | $0 | 14,607 | SEC↗ |
| Wang Theodore T | Director | A Award deriv | 2023-06-07 | 2023-06-09 | 14,607 | — | $0 | 14,607 | SEC↗ |
| Kim Bobae | VP Reg. Affairs & Quality | A Award deriv | 2023-06-07 | 2023-06-09 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Bruder Scott P | Director | A Award deriv | 2023-06-07 | 2023-06-09 | 14,607 | — | $0 | 14,607 | SEC↗ |
| Dekker Martin | See Remarks | A Award deriv | 2023-06-07 | 2023-06-09 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Shah Parag Suresh | VP of Business Operations | A Award deriv | 2023-06-07 | 2023-06-09 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Fernandes Peter | See Remarks | A Award deriv | 2023-06-07 | 2023-06-09 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Puissance Capital Management L | 10% Owner | S Sale | 2023-06-07 | 2023-06-07 | 134,421 | $0.83 | $111.6K | 1,076,841 | SEC↗ |
| Amin Naseem | Director | A Award | 2023-06-07 | 2023-06-09 | 47,578 | — | $0 | 291,865 | SEC↗ |
| Kim Bobae | VP Reg. Affairs & Quality | M Exercise deriv | 2023-05-18 | 2023-05-22 | 266 | — | $0 | 0 | SEC↗ |
| Kim Bobae | VP Reg. Affairs & Quality | M Exercise deriv | 2023-05-18 | 2023-05-22 | 1,022 | — | $0 | 144 | SEC↗ |
| Puissance Capital Management L | 10% Owner | S Sale | 2023-05-18 | 2023-05-19 | 560,000 | $9.46 | $5.30M | 1,211,262 | SEC↗ |
| Kim Bobae | VP Reg. Affairs & Quality | S Sale | 2023-05-18 | 2023-05-22 | 9,455 | $10.00 | $94.5K | 1,723 | SEC↗ |
| Kim Bobae | VP Reg. Affairs & Quality | M Exercise | 2023-05-18 | 2023-05-22 | 266 | $7.35 | $2.0K | 1,723 | SEC↗ |
| Kim Bobae | VP Reg. Affairs & Quality | M Exercise | 2023-05-18 | 2023-05-22 | 1,022 | $7.50 | $7.7K | 1,723 | SEC↗ |
| Bruder Scott P | Director | A Award deriv | 2023-02-10 | 2023-02-14 | 29,000 | $1.52 | $44.1K | 29,000 | SEC↗ |
| Wang Theodore T | Director, 10% Owner | A Award deriv | 2023-02-10 | 2023-02-14 | 29,000 | $1.52 | $44.1K | 29,000 | SEC↗ |
| Cloyd Mary Ann | Director | A Award deriv | 2023-02-10 | 2023-02-14 | 29,000 | $1.52 | $44.1K | 29,000 | SEC↗ |
| Laccona Nicholas | FINANCIAL OFFICER, (PFO & PA | A Award deriv | 2023-02-10 | 2023-02-14 | 50,000 | $1.52 | $76.0K | 50,000 | SEC↗ |
| Fernandes Peter | CHIEF EXECUTIVE OFFICER | A Award deriv | 2023-02-10 | 2023-02-14 | 100,000 | $1.52 | $152.0K | 100,000 | SEC↗ |
| Shah Parag Suresh | VP OF BUSINESS OPERATIONS | A Award deriv | 2023-02-10 | 2023-02-14 | 50,000 | $1.52 | $76.0K | 50,000 | SEC↗ |
| Dekker Martin | VP OF ENGINEERING & MANUFACT | A Award deriv | 2023-02-10 | 2023-02-14 | 50,000 | $1.52 | $76.0K | 50,000 | SEC↗ |
| Teufel Crispin | Director | A Award deriv | 2023-02-10 | 2023-02-14 | 29,000 | $1.52 | $44.1K | 29,000 | SEC↗ |
| Amin Naseem | Director | A Award | 2023-02-10 | 2023-02-14 | 84,000 | — | $0 | 244,287 | SEC↗ |
| Laccona Nicholas | FINANCIAL OFFICER, (PFO & PA | M Exercise deriv | 2022-12-09 | 2022-12-13 | 18,000 | — | $0 | 18,000 | SEC↗ |
| Shah Parag Suresh | VP OF BUSINESS OPERATIONS | M Exercise deriv | 2022-12-09 | 2022-12-13 | 25,500 | — | $0 | 25,500 | SEC↗ |
| Fernandes Peter | PRINCIPAL EXECUTIVE OFFICER | M Exercise deriv | 2022-12-09 | 2022-12-13 | 32,500 | — | $0 | 32,500 | SEC↗ |
| Dekker Martin | VP OF ENGINEERING & MANUFACT | M Exercise deriv | 2022-12-09 | 2022-12-13 | 25,500 | — | $0 | 25,500 | SEC↗ |
| Laccona Nicholas | FINANCIAL OFFICER, (PFO & PA | F Tax w/h | 2022-12-09 | 2022-12-13 | 5,530 | $0.93 | $5.1K | 12,470 | SEC↗ |
| Laccona Nicholas | FINANCIAL OFFICER, (PFO & PA | M Exercise | 2022-12-09 | 2022-12-13 | 18,000 | — | $0 | 18,000 | SEC↗ |
| Shah Parag Suresh | VP OF BUSINESS OPERATIONS | F Tax w/h | 2022-12-09 | 2022-12-13 | 7,834 | $0.93 | $7.3K | 17,666 | SEC↗ |
| Shah Parag Suresh | VP OF BUSINESS OPERATIONS | M Exercise | 2022-12-09 | 2022-12-13 | 25,500 | — | $0 | 25,500 | SEC↗ |
| Fernandes Peter | PRINCIPAL EXECUTIVE OFFICER | M Exercise | 2022-12-09 | 2022-12-13 | 32,500 | — | $0 | 32,500 | SEC↗ |
| Fernandes Peter | PRINCIPAL EXECUTIVE OFFICER | F Tax w/h | 2022-12-09 | 2022-12-13 | 9,985 | $0.93 | $9.3K | 22,515 | SEC↗ |
| Dekker Martin | VP OF ENGINEERING & MANUFACT | F Tax w/h | 2022-12-09 | 2022-12-13 | 7,834 | $0.93 | $7.3K | 17,666 | SEC↗ |
| Dekker Martin | VP OF ENGINEERING & MANUFACT | M Exercise | 2022-12-09 | 2022-12-13 | 25,500 | — | $0 | 25,500 | SEC↗ |
| Laccona Nicholas | FINANCIAL OFFICER, (PFO & PA | A Award deriv | 2022-01-26 | 2022-01-28 | 36,000 | — | $0 | 36,000 | SEC↗ |
| Shah Parag Suresh | VP OF BUSINESS OPERATIONS | A Award deriv | 2022-01-26 | 2022-01-28 | 51,000 | — | $0 | 51,000 | SEC↗ |
| Dekker Martin | VP OF ENGINEERING & MANUFACT | A Award deriv | 2022-01-26 | 2022-01-28 | 51,000 | — | $0 | 51,000 | SEC↗ |
| Fernandes Peter | CHIEF REGULATORY & SAFETY OF | A Award deriv | 2022-01-26 | 2022-01-28 | 65,000 | — | $0 | 65,000 | SEC↗ |
| Amin Naseem | Director | A Award deriv | 2021-12-31 | 2022-01-04 | 8,671 | $3.10 | $26.9K | 23,809 | SEC↗ |
| Bruder Scott P | Director | A Award deriv | 2021-12-31 | 2022-01-04 | 21,828 | $3.10 | $67.7K | 36,966 | SEC↗ |
| Cloyd Mary Ann | Director | A Award deriv | 2021-12-31 | 2022-01-04 | 21,828 | $3.10 | $67.7K | 36,300 | SEC↗ |
| Teufel Crispin | Director | A Award deriv | 2021-12-31 | 2022-01-04 | 21,828 | $3.10 | $67.7K | 33,087 | SEC↗ |
| Wang Theodore T | Director, 10% Owner | A Award deriv | 2021-12-31 | 2022-01-04 | 21,828 | $3.10 | $67.7K | 35,634 | SEC↗ |
| Amin Naseem | Director | A Award | 2021-12-31 | 2022-01-04 | 39,032 | — | $0 | 160,287 | SEC↗ |
| Puissance Capital Management L | 10% Owner | A Award | 2021-06-07 | 2021-06-08 | 8,189 | $4.00 | $32.8K | 1,771,262 | SEC↗ |
| Puissance Life Science Opportu | 10% Owner | A Award deriv | 2021-04-26 | 2021-04-26 | 304,286 | — | $0 | 685,236 | SEC↗ |
| Puissance Life Science Opportu | 10% Owner | A Award deriv | 2021-04-26 | 2021-04-26 | 380,950 | — | $0 | 380,950 | SEC↗ |
| Puissance Life Science Opportu | 10% Owner | A Award | 2021-04-26 | 2021-04-26 | 609,231 | $4.00 | $2.44M | 1,763,077 | SEC↗ |
| Peacock Jonathan M | Director | A Award | 2021-03-31 | 2021-04-02 | 15,308 | — | $0 | 157,033 | SEC↗ |
| New Mountain Capital, L.L.C. | 10% Owner | S Sale | 2021-03-18 | 2021-03-22 | 400,000 | $5.48 | $2.19M | 609,231 | SEC↗ |
| Amin Naseem | Director | A Award deriv | 2020-09-10 | 2020-09-14 | 6,509 | $10.12 | $65.9K | 15,138 | SEC↗ |
| Bruder Scott P | Director | A Award deriv | 2020-09-10 | 2020-09-14 | 6,509 | $10.12 | $65.9K | 15,138 | SEC↗ |
| Cloyd Mary Ann | Director | A Award deriv | 2020-09-10 | 2020-09-14 | 6,509 | $10.12 | $65.9K | 14,472 | SEC↗ |
| BENNETT MATTHEW | Director | A Award deriv | 2020-09-10 | 2020-09-14 | 6,509 | $10.12 | $65.9K | 6,509 | SEC↗ |
| Moura Andre V. | Director | A Award deriv | 2020-09-10 | 2020-09-14 | 6,509 | $10.12 | $65.9K | 13,472 | SEC↗ |
| Teufel Crispin | Director | A Award deriv | 2020-09-10 | 2020-09-14 | 6,509 | $10.12 | $65.9K | 11,259 | SEC↗ |
| Wang Theodore T | Director, 10% Owner | A Award deriv | 2020-09-10 | 2020-09-14 | 6,509 | $10.12 | $65.9K | 13,806 | SEC↗ |
| FARES Wassim | Chief Medical Officer | A Award deriv | 2020-09-10 | 2020-09-14 | 30,000 | $10.12 | $303.6K | 30,000 | SEC↗ |
| FARES Wassim | Chief Medical Officer | P Buy | 2020-09-10 | 2020-09-14 | 4,000 | $10.18 | $40.7K | 4,000 | SEC↗ |
| Wang Theodore T | Director, 10% Owner | P Buy | 2020-06-08 | 2020-06-09 | 2,600 | $12.87 | $33.5K | 60,913 | SEC↗ |
| Wang Theodore T | Director, 10% Owner | P Buy | 2020-06-05 | 2020-06-09 | 4,986 | $12.72 | $63.4K | 58,313 | SEC↗ |
| Puissance Capital Fund (GP) LL | 10% Owner | A Award | 2020-05-21 | 2020-05-22 | 1,153,846 | $13.00 | $15.00M | 1,153,846 | SEC↗ |
| Puissance Cross-Border Opportu | 10% Owner | J Other | 2020-04-17 | 2020-04-20 | 553,250 | — | $0 | 0 | SEC↗ |
| Peacock Jonathan M | Director | A Award | 2020-01-23 | 2020-01-27 | 350,000 | — | $0 | 2,225,920 | SEC↗ |
| Wang Theodore T | Director, 10% Owner | P Buy | 2019-11-25 | 2019-11-25 | 7,193 | $0.39 | $2.8K | 592,922 | SEC↗ |
| Wang Theodore T | Director, 10% Owner | P Buy | 2019-11-22 | 2019-11-25 | 1,050 | $0.37 | $389 | 585,729 | SEC↗ |
| Wang Theodore T | Director, 10% Owner | P Buy | 2019-11-21 | 2019-11-25 | 200 | $0.37 | $74 | 584,679 | SEC↗ |
| Korner Assaf | CFO | F Tax w/h | 2019-11-15 | 2019-11-19 | 32,987 | $0.34 | $11.2K | 66,078 | SEC↗ |
| Dekker Martin | VP of Engineering & Manuf | F Tax w/h | 2019-11-15 | 2019-11-19 | 27,134 | $0.34 | $9.2K | 124,619 | SEC↗ |
| Tenenbaum Fabian | Chief Executive Officer | F Tax w/h | 2019-11-15 | 2019-11-19 | 76,823 | $0.34 | $26.1K | 407,459 | SEC↗ |
| Fernandes Peter | Chief Regulatory & Safety Of | F Tax w/h | 2019-11-15 | 2019-11-19 | 40,280 | $0.34 | $13.7K | 182,022 | SEC↗ |
| Shah Parag Suresh | VP of Business Operations | F Tax w/h | 2019-11-15 | 2019-11-19 | 25,993 | $0.34 | $8.8K | 105,606 | SEC↗ |
| Venrock Management IV, LLC | 10% Owner | S Sale | 2019-10-28 | 2019-10-28 | 333,010 | $0.44 | $146.5K | 6,435,173 | SEC↗ |
| Venrock Healthcare Capital Par | 10% Owner | S Sale | 2019-10-28 | 2019-10-28 | 333,010 | $0.44 | $146.5K | 6,435,173 | SEC↗ |
| Venrock Management IV, LLC | 10% Owner | S Sale | 2019-10-25 | 2019-10-28 | 56,242 | $0.45 | $25.3K | 6,768,183 | SEC↗ |
| Venrock Healthcare Capital Par | 10% Owner | S Sale | 2019-10-25 | 2019-10-28 | 56,242 | $0.45 | $25.3K | 6,768,183 | SEC↗ |
| Venrock Management IV, LLC | 10% Owner | S Sale | 2019-10-24 | 2019-10-28 | 704,595 | $0.50 | $352.3K | 6,824,425 | SEC↗ |
| Venrock Healthcare Capital Par | 10% Owner | S Sale | 2019-10-24 | 2019-10-28 | 704,595 | $0.50 | $352.3K | 6,824,425 | SEC↗ |
| Edmonds Amy | VP Clinical Operations & Adm | A Award deriv | 2019-09-26 | 2019-09-30 | 175,500 | — | $0 | 445,886 | SEC↗ |
| BENNETT MATTHEW | Director | A Award deriv | 2019-09-26 | 2019-09-30 | 46,266 | — | $0 | 84,482 | SEC↗ |
| Amin Naseem | Director | A Award deriv | 2019-09-26 | 2019-09-30 | 46,266 | — | $0 | 109,482 | SEC↗ |
| Korner Assaf | CFO | A Award deriv | 2019-09-26 | 2019-09-30 | 175,500 | — | $0 | 425,500 | SEC↗ |
| Bruder Scott P | Director | A Award deriv | 2019-09-26 | 2019-09-30 | 46,266 | — | $0 | 129,482 | SEC↗ |
| Cloyd Mary Ann | Director | A Award deriv | 2019-09-26 | 2019-09-30 | 46,266 | — | $0 | 119,482 | SEC↗ |
| Dekker Martin | VP of Engineering & Manuf | A Award deriv | 2019-09-26 | 2019-09-30 | 175,500 | — | $0 | 438,483 | SEC↗ |
| Tenenbaum Fabian | Chief Executive Officer | A Award deriv | 2019-09-26 | 2019-09-30 | 1,752,000 | — | $0 | 5,440,697 | SEC↗ |
| Fernandes Peter | Chief Regulatory & Safety Of | A Award deriv | 2019-09-26 | 2019-09-30 | 175,500 | — | $0 | 470,290 | SEC↗ |
| Moura Andre V. | Director | A Award deriv | 2019-09-26 | 2019-09-30 | 46,266 | — | $0 | 104,482 | SEC↗ |
| Shah Parag Suresh | VP Proj Mgmt & Distribution | A Award deriv | 2019-09-26 | 2019-09-30 | 175,500 | — | $0 | 445,854 | SEC↗ |
| Teufel Crispin | Director | A Award deriv | 2019-09-26 | 2019-09-30 | 46,266 | — | $0 | 71,266 | SEC↗ |
| Wang Theodore T | Director, 10% Owner | A Award deriv | 2019-09-26 | 2019-09-30 | 46,266 | — | $0 | 109,482 | SEC↗ |
| Wang Theodore T | Director, 10% Owner | P Buy | 2019-06-12 | 2019-06-14 | 50,000 | $0.64 | $32.0K | 584,479 | SEC↗ |
| Teufel Crispin | Director | A Award deriv | 2019-06-06 | 2019-06-10 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Edmonds Amy | VP Clinical Operations & Adm | F Tax w/h | 2019-05-22 | 2019-05-23 | 35,827 | $0.61 | $21.9K | 140,216 | SEC↗ |
| Wang Theodore T | Director, 10% Owner | P Buy | 2019-05-22 | 2019-05-24 | 27,500 | $0.60 | $16.5K | 534,479 | SEC↗ |
| Tenenbaum Fabian | Chief Executive Officer | P Buy | 2019-05-21 | 2019-05-22 | 5,000 | $0.60 | $3.0K | 484,282 | SEC↗ |
| Peacock Jonathan M | Director | P Buy | 2019-05-21 | 2019-05-22 | 20,000 | $0.61 | $12.2K | 1,875,920 | SEC↗ |
| Wang Theodore T | Director, 10% Owner | P Buy | 2019-05-21 | 2019-05-22 | 43,280 | $0.61 | $26.4K | 506,979 | SEC↗ |
| Amin Naseem | Director | P Buy | 2019-01-25 | 2019-01-25 | 571,429 | $0.70 | $400.0K | 1,818,867 | SEC↗ |
| Peacock Jonathan M | Director | P Buy | 2019-01-25 | 2019-01-25 | 714,286 | $0.70 | $500.0K | 1,855,920 | SEC↗ |
| Wang Theodore T | Director, 10% Owner | P Buy | 2019-01-25 | 2019-01-25 | 450,000 | $0.70 | $315.0K | 463,699 | SEC↗ |
| Peacock Jonathan M | Director | A Award | 2019-01-23 | 2019-01-25 | 227,273 | — | $0 | 1,141,634 | SEC↗ |
| VENROCK ASSOCIATES IV L P | 10% Owner | P Buy | 2019-01-23 | 2019-03-14 | 142,857 | $0.70 | $100.0K | 7,529,020 | SEC↗ |
| Shah Nimish P | 10% Owner | P Buy | 2019-01-23 | 2019-03-14 | 142,857 | $0.70 | $100.0K | 7,529,020 | SEC↗ |
| Korner Assaf | CFO | A Award deriv | 2019-01-02 | 2019-01-04 | 12,500 | — | $0 | 250,000 | SEC↗ |
| Dekker Martin | VP of Engineering & Manuf | A Award deriv | 2019-01-02 | 2019-01-04 | 12,500 | — | $0 | 262,983 | SEC↗ |
| Edmonds Amy | VP Clinical Operations & Adm | A Award deriv | 2019-01-02 | 2019-01-04 | 12,500 | — | $0 | 270,386 | SEC↗ |
| Tenenbaum Fabian | Chief Executive Officer | A Award deriv | 2019-01-02 | 2019-01-04 | 12,500 | — | $0 | 3,688,697 | SEC↗ |
| Fernandes Peter | Chief Regulatory & Safety Of | A Award deriv | 2019-01-02 | 2019-01-04 | 12,500 | — | $0 | 294,790 | SEC↗ |
| Shah Parag Suresh | VP Proj Mgmt & Distribution | A Award deriv | 2019-01-02 | 2019-01-04 | 12,500 | — | $0 | 260,000 | SEC↗ |
| Korner Assaf | CFO | A Award deriv | 2018-11-20 | 2018-11-23 | 137,500 | — | $0 | 237,500 | SEC↗ |
| Dekker Martin | VP of Engineering & Manuf | A Award deriv | 2018-11-20 | 2018-11-23 | 137,500 | — | $0 | 250,483 | SEC↗ |
| Edmonds Amy | VP Clinical Operations & Adm | A Award deriv | 2018-11-20 | 2018-11-23 | 137,500 | — | $0 | 257,886 | SEC↗ |
| Tenenbaum Fabian | Chief Executive Officer | A Award deriv | 2018-11-20 | 2018-11-23 | 1,487,500 | — | $0 | 3,676,197 | SEC↗ |
| Fernandes Peter | Chief Regulatory & Safety Of | A Award deriv | 2018-11-20 | 2018-11-23 | 137,500 | — | $0 | 282,290 | SEC↗ |
| Shah Parag Suresh | VP Proj Mgmt & Distribution | A Award deriv | 2018-11-20 | 2018-11-23 | 137,500 | — | $0 | 247,500 | SEC↗ |
| Korner Assaf | CFO | A Award | 2018-09-25 | 2018-09-27 | 99,065 | — | $0 | 99,065 | SEC↗ |
| Tenenbaum Fabian | Chief Executive Officer | A Award | 2018-09-25 | 2018-09-27 | 224,299 | — | $0 | 479,282 | SEC↗ |
| Fernandes Peter | Chief Regulatory & Safety Of | A Award | 2018-09-25 | 2018-09-27 | 119,626 | — | $0 | 222,302 | SEC↗ |
| Shah Parag Suresh | VP Proj Mgmt & Distribution | A Award | 2018-09-25 | 2018-09-27 | 78,505 | — | $0 | 131,599 | SEC↗ |
| Dekker Martin | VP of Engineering & Manuf | A Award | 2018-09-25 | 2018-09-27 | 82,243 | — | $0 | 151,753 | SEC↗ |
| Edmonds Amy | VP Clinical Operations & Adm | A Award | 2018-09-25 | 2018-09-27 | 82,243 | — | $0 | 176,043 | SEC↗ |
| Venrock Partners, L.P. | 10% Owner | P Buy | 2018-09-17 | 2018-09-17 | 60,000 | $1.18 | $70.8K | 7,386,163 | SEC↗ |
| VHCP Management III, LLC | 10% Owner | P Buy | 2018-09-17 | 2018-09-17 | 60,000 | $1.18 | $70.8K | 7,386,163 | SEC↗ |
| Venrock Partners, L.P. | 10% Owner | P Buy | 2018-09-14 | 2018-09-17 | 75,000 | $1.23 | $92.3K | 7,326,163 | SEC↗ |
| VHCP Management III, LLC | 10% Owner | P Buy | 2018-09-14 | 2018-09-17 | 75,000 | $1.23 | $92.3K | 7,326,163 | SEC↗ |
| Venrock Partners, L.P. | 10% Owner | P Buy | 2018-09-13 | 2018-09-17 | 75,000 | $1.19 | $89.3K | 7,251,163 | SEC↗ |
| VHCP Management III, LLC | 10% Owner | P Buy | 2018-09-13 | 2018-09-17 | 75,000 | $1.19 | $89.3K | 7,251,163 | SEC↗ |
| VHCP Co-Investment Holdings II | 10% Owner | P Buy | 2018-09-12 | 2018-09-12 | 75,000 | $1.15 | $86.3K | 7,176,163 | SEC↗ |
| Venrock Healthcare Capital Par | 10% Owner | P Buy | 2018-09-12 | 2018-09-12 | 75,000 | $1.15 | $86.3K | 7,176,163 | SEC↗ |
| VHCP Co-Investment Holdings II | 10% Owner | P Buy | 2018-09-11 | 2018-09-12 | 200,000 | $1.14 | $228.0K | 7,101,163 | SEC↗ |
| Venrock Healthcare Capital Par | 10% Owner | P Buy | 2018-09-11 | 2018-09-12 | 200,000 | $1.14 | $228.0K | 7,101,163 | SEC↗ |
| VHCP Co-Investment Holdings II | 10% Owner | P Buy | 2018-09-10 | 2018-09-12 | 200,000 | $1.22 | $244.0K | 6,901,163 | SEC↗ |
| Venrock Healthcare Capital Par | 10% Owner | P Buy | 2018-09-10 | 2018-09-12 | 200,000 | $1.22 | $244.0K | 6,901,163 | SEC↗ |
| VHCP Co-Investment Holdings II | 10% Owner | P Buy | 2018-09-07 | 2018-09-07 | 60,000 | $0.90 | $54.0K | 6,701,163 | SEC↗ |
| Venrock Partners Management, L | 10% Owner | P Buy | 2018-09-07 | 2018-09-07 | 60,000 | $0.90 | $54.0K | 6,701,163 | SEC↗ |
| VHCP Co-Investment Holdings II | 10% Owner | P Buy | 2018-09-06 | 2018-09-07 | 50,000 | $0.84 | $42.0K | 6,641,163 | SEC↗ |
| Venrock Partners Management, L | 10% Owner | P Buy | 2018-09-06 | 2018-09-07 | 50,000 | $0.84 | $42.0K | 6,641,163 | SEC↗ |
| VHCP Co-Investment Holdings II | 10% Owner | P Buy | 2018-09-05 | 2018-09-07 | 50,000 | $0.85 | $42.5K | 6,591,163 | SEC↗ |
| Venrock Partners Management, L | 10% Owner | P Buy | 2018-09-05 | 2018-09-07 | 50,000 | $0.85 | $42.5K | 6,591,163 | SEC↗ |
| Venrock Partners, L.P. | 10% Owner | P Buy | 2018-08-16 | 2018-08-16 | 66,393 | $0.65 | $43.2K | 6,541,163 | SEC↗ |
| Shah Nimish P | 10% Owner | P Buy | 2018-08-16 | 2018-08-16 | 66,393 | $0.65 | $43.2K | 6,541,163 | SEC↗ |
| Venrock Partners, L.P. | 10% Owner | P Buy | 2018-08-15 | 2018-08-16 | 272,000 | $0.65 | $176.8K | 6,474,770 | SEC↗ |
| Shah Nimish P | 10% Owner | P Buy | 2018-08-15 | 2018-08-16 | 272,000 | $0.65 | $176.8K | 6,474,770 | SEC↗ |
| Venrock Partners, L.P. | 10% Owner | P Buy | 2018-08-14 | 2018-08-16 | 190,977 | $0.65 | $124.1K | 6,202,770 | SEC↗ |
| Shah Nimish P | 10% Owner | P Buy | 2018-08-14 | 2018-08-16 | 190,977 | $0.65 | $124.1K | 6,202,770 | SEC↗ |
| BENNETT MATTHEW | Director | A Award | 2018-06-21 | 2018-06-25 | 11,987 | — | $0 | 30,552 | SEC↗ |
| Amin Naseem | Director | A Award | 2018-06-21 | 2018-06-25 | 17,124 | — | $0 | 1,247,438 | SEC↗ |
| Wang Theodore T | Director, 10% Owner | A Award | 2018-06-21 | 2018-06-25 | 13,699 | — | $0 | 13,699 | SEC↗ |
| Luehring Jens | Director | A Award | 2018-06-21 | 2018-06-25 | 14,555 | — | $0 | 95,213 | SEC↗ |
| Tasse Daniel | Director | A Award | 2018-06-21 | 2018-06-25 | 11,987 | — | $0 | 182,604 | SEC↗ |
| Moura Andre V. | Director | A Award | 2018-06-21 | 2018-06-25 | 15,411 | — | $0 | 68,736 | SEC↗ |
| Dekker Martin | VP of Engineering & Manuf | F Tax w/h | 2018-06-12 | 2018-06-14 | 7,473 | $2.37 | $17.7K | 69,510 | SEC↗ |
| Fernandes Peter | Chief Regulatory & Safety Of | F Tax w/h | 2018-06-12 | 2018-06-14 | 11,304 | $2.37 | $26.8K | 102,676 | SEC↗ |
| Tenenbaum Fabian | Chief Executive Officer | F Tax w/h | 2018-06-12 | 2018-06-14 | 63,486 | $2.37 | $150.5K | 254,983 | SEC↗ |
| Edmonds Amy | VP Clinical Operations & Adm | F Tax w/h | 2018-06-12 | 2018-06-14 | 7,499 | $2.37 | $17.8K | 93,800 | SEC↗ |
| Shah Parag Suresh | VP Proj Mgmt & Distribution | F Tax w/h | 2018-06-12 | 2018-06-14 | 7,144 | $2.37 | $16.9K | 53,094 | SEC↗ |
| Quinn Deborah | Chief Medical Officer | F Tax w/h | 2018-06-12 | 2018-06-14 | 10,541 | $2.37 | $25.0K | 94,070 | SEC↗ |
| Wang Theodore T | Director, 10% Owner | A Award deriv | 2018-06-05 | 2018-06-07 | 38,216 | $2.27 | $86.8K | 63,216 | SEC↗ |
| Amin Naseem | Director | A Award deriv | 2018-06-05 | 2018-06-07 | 38,216 | $2.27 | $86.8K | 83,216 | SEC↗ |
| Luehring Jens | Director | A Award deriv | 2018-06-05 | 2018-06-07 | 38,216 | $2.27 | $86.8K | 58,216 | SEC↗ |
| Cloyd Mary Ann | Director | A Award deriv | 2018-06-05 | 2018-06-07 | 38,216 | $2.27 | $86.8K | 73,216 | SEC↗ |
| Moura Andre V. | Director | A Award deriv | 2018-06-05 | 2018-06-07 | 38,216 | $2.27 | $86.8K | 58,216 | SEC↗ |
| Bruder Scott P | Director | A Award deriv | 2018-06-05 | 2018-06-07 | 38,216 | $2.27 | $86.8K | 83,216 | SEC↗ |
| Tasse Daniel | Director | A Award deriv | 2018-06-05 | 2018-06-07 | 38,216 | $2.27 | $86.8K | 58,216 | SEC↗ |
| BENNETT MATTHEW | Director | A Award deriv | 2018-06-05 | 2018-06-07 | 38,216 | $2.27 | $86.8K | 38,216 | SEC↗ |
| Peacock Jonathan M | Director | A Award | 2018-04-02 | 2018-04-03 | 99,010 | — | $0 | 914,361 | SEC↗ |
| Korner Assaf | CFO | A Award deriv | 2018-01-17 | 2018-01-17 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Edmonds Amy | VP Clinical Operations & Adm | A Award deriv | 2018-01-12 | 2018-01-17 | 80,000 | — | $0 | 80,000 | SEC↗ |
| Quinn Deborah | Chief Medical Officer | A Award deriv | 2018-01-12 | 2018-01-17 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Tenenbaum Fabian | Chief Executive Officer | A Award deriv | 2018-01-12 | 2018-01-17 | 550,000 | — | $0 | 550,000 | SEC↗ |
| Fernandes Peter | Chief Regulatory & Safety Of | A Award deriv | 2018-01-12 | 2018-01-17 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Shah Parag Suresh | VP Proj Mgmt & Distribution | A Award deriv | 2018-01-12 | 2018-01-17 | 80,000 | — | $0 | 80,000 | SEC↗ |
| Dekker Martin | VP of Engineering & Manuf | A Award deriv | 2018-01-12 | 2018-01-17 | 80,000 | — | $0 | 80,000 | SEC↗ |
| Edmonds Amy | VP Clinical Operations & Adm | A Award | 2018-01-12 | 2018-01-17 | 21,675 | — | $0 | 101,299 | SEC↗ |
| Quinn Deborah | Chief Medical Officer | A Award | 2018-01-12 | 2018-01-17 | 29,557 | — | $0 | 104,611 | SEC↗ |
| Tenenbaum Fabian | Chief Executive Officer | A Award | 2018-01-12 | 2018-01-17 | 55,419 | — | $0 | 318,469 | SEC↗ |
| Fernandes Peter | Chief Regulatory & Safety Of | A Award | 2018-01-12 | 2018-01-17 | 31,527 | — | $0 | 113,980 | SEC↗ |
| Shah Parag Suresh | VP Proj Mgmt & Distribution | A Award | 2018-01-12 | 2018-01-17 | 20,690 | — | $0 | 60,238 | SEC↗ |
| Dekker Martin | VP of Engineering & Manuf | A Award | 2018-01-12 | 2018-01-17 | 21,675 | — | $0 | 76,983 | SEC↗ |
| Quinn Deborah | Chief Medical Officer | F Tax w/h | 2018-01-04 | 2018-01-08 | 33,114 | $2.49 | $82.5K | 75,054 | SEC↗ |
| Dekker Martin | VP of Engineering & Manuf | F Tax w/h | 2018-01-04 | 2018-01-08 | 24,284 | $2.49 | $60.5K | 55,308 | SEC↗ |
| Shah Parag Suresh | VP Proj Mgmt & Distribution | F Tax w/h | 2018-01-04 | 2018-01-08 | 23,180 | $2.49 | $57.7K | 39,548 | SEC↗ |
| Fernandes Peter | Chief Regulatory & Safety Of | F Tax w/h | 2018-01-04 | 2018-01-08 | 35,321 | $2.49 | $87.9K | 82,453 | SEC↗ |
| Schoeps Megan | Principal Financial Officer | M Exercise deriv | 2017-12-13 | 2017-12-13 | 1,000 | — | $0 | 3,000 | SEC↗ |
| Schoeps Megan | Principal Financial Officer | M Exercise | 2017-12-13 | 2017-12-13 | 1,000 | $0.49 | $490 | 19,248 | SEC↗ |
| Wang Theodore T | Director, 10% Owner | A Award deriv | 2017-12-12 | 2017-12-14 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Peacock Jonathan M | Director | P Buy deriv | 2017-09-29 | 2017-10-03 | 248,962 | — | $0 | 248,962 | SEC↗ |
| Luehring Jens | Director, 10% Owner | P Buy deriv | 2017-09-29 | 2017-10-03 | 10,000 | — | $0 | 10,000 | SEC↗ |
| Amin Naseem | Director | P Buy deriv | 2017-09-29 | 2017-10-03 | 456,432 | — | $0 | 456,432 | SEC↗ |
| Peacock Jonathan M | Director | P Buy | 2017-09-29 | 2017-10-03 | 248,962 | — | $0 | 815,351 | SEC↗ |
| Luehring Jens | Director, 10% Owner | P Buy | 2017-09-29 | 2017-10-03 | 10,000 | — | $0 | 80,658 | SEC↗ |
| Amin Naseem | Director | P Buy | 2017-09-29 | 2017-10-03 | 456,432 | — | $0 | 1,230,314 | SEC↗ |
| Moura Andre V. | Director | A Award deriv | 2017-09-22 | 2017-09-26 | 10,000 | — | $0 | 10,000 | SEC↗ |
| Weinstein Adam | Director, 10% Owner | A Award deriv | 2017-09-22 | 2017-09-26 | 10,000 | — | $0 | 10,000 | SEC↗ |
| Peacock Jonathan M | Director | A Award deriv | 2017-09-22 | 2017-09-26 | 10,000 | — | $0 | 10,000 | SEC↗ |
| Luehring Jens | Director, 10% Owner | A Award deriv | 2017-09-22 | 2017-09-26 | 10,000 | — | $0 | 10,000 | SEC↗ |
| Tasse Daniel | Director | A Award deriv | 2017-09-22 | 2017-09-26 | 10,000 | — | $0 | 10,000 | SEC↗ |
| Bruder Scott P | Director | A Award deriv | 2017-09-22 | 2017-09-26 | 10,000 | — | $0 | 10,000 | SEC↗ |
| Amin Naseem | Director | A Award deriv | 2017-09-22 | 2017-09-26 | 10,000 | — | $0 | 10,000 | SEC↗ |
| Cloyd Mary Ann | Director | A Award deriv | 2017-09-22 | 2017-09-26 | 10,000 | — | $0 | 10,000 | SEC↗ |
| Amin Naseem | Director | A Award | 2017-06-28 | 2017-07-03 | 36,232 | — | $0 | 773,882 | SEC↗ |
| Weinstein Adam | Director, 10% Owner | A Award | 2017-06-28 | 2017-07-03 | 25,363 | — | $0 | 42,130 | SEC↗ |
| Tasse Daniel | Director | A Award | 2017-06-28 | 2017-06-30 | 25,363 | — | $0 | 170,617 | SEC↗ |
| Moura Andre V. | Director | A Award | 2017-06-28 | 2017-06-30 | 32,609 | — | $0 | 53,325 | SEC↗ |
| Luehring Jens | Director, 10% Owner | A Award | 2017-06-28 | 2017-06-30 | 30,798 | — | $0 | 70,658 | SEC↗ |
| Peacock Jonathan M | Director | A Award | 2017-06-28 | 2017-06-30 | 57,972 | — | $0 | 566,389 | SEC↗ |
| Schoeps Megan | Principal Financial Officer | F Tax w/h | 2017-05-17 | 2017-05-19 | 10,459 | $1.40 | $14.6K | 18,248 | SEC↗ |
| Tenenbaum Fabian | Chief Executive Officer | A Award | 2017-03-16 | 2017-03-20 | 120,193 | — | $0 | 263,050 | SEC↗ |
| Dekker Martin | VP of Engineering & Manuf | A Award | 2017-03-16 | 2017-03-20 | 56,411 | — | $0 | 79,592 | SEC↗ |
| Edmonds Amy | VP Clinical Operations & Adm | A Award | 2017-03-16 | 2017-03-20 | 56,411 | — | $0 | 79,624 | SEC↗ |
| Fernandes Peter | Chief Regulatory & Safety Of | A Award | 2017-03-16 | 2017-03-20 | 82,052 | — | $0 | 117,774 | SEC↗ |
| Quinn Deborah | Chief Medical Officer | A Award | 2017-03-16 | 2017-03-20 | 76,924 | — | $0 | 108,168 | SEC↗ |
| Shah Parag Suresh | VP Proj Mgmt & Distribution | A Award | 2017-03-16 | 2017-03-20 | 53,847 | — | $0 | 62,728 | SEC↗ |
| Schoeps Megan | Principal Financial Officer | A Award | 2017-03-16 | 2017-03-20 | 24,039 | — | $0 | 28,707 | SEC↗ |
| Luehring Jens | Director, 10% Owner | P Buy | 2016-12-09 | 2016-12-12 | 20,000 | $0.56 | $11.2K | 39,860 | SEC↗ |
| Tenenbaum Fabian | Chief Executive Officer | A Award deriv | 2016-12-07 | 2016-12-09 | 1,042,556 | — | $0 | 1,042,556 | SEC↗ |
| Edmonds Amy | VP Clinical Operations & Adm | A Award deriv | 2016-12-07 | 2016-12-09 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Fernandes Peter | Chief Regulatory Officer | A Award deriv | 2016-12-07 | 2016-12-09 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Quinn Deborah | Chief Medical Officer | A Award deriv | 2016-12-07 | 2016-12-09 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Shah Parag Suresh | VP Proj Mgmt & Distribution | A Award deriv | 2016-12-07 | 2016-12-09 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Dekker Martin | VP of Device Engineering | A Award deriv | 2016-12-07 | 2016-12-09 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Peacock Jonathan M | Director | A Award deriv | 2016-12-07 | 2016-12-09 | 588,373 | — | $0 | 588,373 | SEC↗ |
| Peacock Jonathan M | Director | P Buy deriv | 2016-11-29 | 2016-11-30 | 285,715 | — | $0 | 285,715 | SEC↗ |
| Tenenbaum Fabian | Chief Executive Officer | P Buy deriv | 2016-11-29 | 2016-12-01 | 142,857 | — | $0 | 142,857 | SEC↗ |
| Amin Naseem | Director | P Buy deriv | 2016-11-29 | 2016-12-01 | 714,285 | — | $0 | 714,285 | SEC↗ |
| Peacock Jonathan M | Director | P Buy | 2016-11-29 | 2016-11-30 | 285,715 | — | $0 | 508,417 | SEC↗ |
| Tenenbaum Fabian | Chief Executive Officer | P Buy | 2016-11-29 | 2016-12-01 | 142,857 | — | $0 | 142,857 | SEC↗ |
| Amin Naseem | Director | P Buy | 2016-11-29 | 2016-12-01 | 714,285 | — | $0 | 737,650 | SEC↗ |
| Tenenbaum Fabian | Chief Executive Officer | A Award deriv | 2016-11-11 | 2016-11-15 | 466,141 | — | $0 | 466,141 | SEC↗ |
| Fernandes Peter | Chief Regulatory Officer | F Tax w/h | 2016-09-12 | 2016-09-13 | 19,785 | $1.38 | $27.3K | 35,722 | SEC↗ |
| Edmonds Amy | VP Clinical Operations & Adm | F Tax w/h | 2016-09-12 | 2016-09-13 | 13,301 | $1.38 | $18.4K | 23,213 | SEC↗ |
| Dekker Martin | VP of Device Engineering | F Tax w/h | 2016-09-12 | 2016-09-13 | 13,333 | $1.38 | $18.4K | 23,181 | SEC↗ |
| Shah Parag Suresh | VP Proj Mgmt & Distribution | F Tax w/h | 2016-09-12 | 2016-09-13 | 4,673 | $1.38 | $6.4K | 8,881 | SEC↗ |
| Quinn Deborah | Chief Medical Officer | F Tax w/h | 2016-09-12 | 2016-09-13 | 18,548 | $1.38 | $25.6K | 31,244 | SEC↗ |
| Luehring Jens | Director, 10% Owner | A Award deriv | 2016-06-17 | 2016-06-21 | 10,000 | — | $0 | 10,000 | SEC↗ |
| Moura Andre V. | Director | A Award deriv | 2016-06-17 | 2016-06-21 | 10,000 | — | $0 | 10,000 | SEC↗ |
| Tasse Daniel | Director | A Award deriv | 2016-06-17 | 2016-06-21 | 10,000 | — | $0 | 10,000 | SEC↗ |
| Holt Matthew S. | Director, 10% Owner | A Award deriv | 2016-06-17 | 2016-06-21 | 10,000 | — | $0 | 10,000 | SEC↗ |
| Weinstein Adam | Director, 10% Owner | A Award deriv | 2016-06-17 | 2016-06-21 | 10,000 | — | $0 | 10,000 | SEC↗ |
| Bruder Scott P | Director | A Award deriv | 2016-06-17 | 2016-06-21 | 10,000 | — | $0 | 10,000 | SEC↗ |
| Amin Naseem | Director | A Award deriv | 2016-06-17 | 2016-06-21 | 10,000 | — | $0 | 10,000 | SEC↗ |
| Peacock Jonathan M | President and CEO | P Buy | 2016-05-17 | 2016-05-18 | 5,000 | $1.37 | $6.9K | 222,702 | SEC↗ |
| Tasse Daniel | Director | A Award | 2016-04-28 | 2016-04-29 | 16,356 | — | $0 | 145,254 | SEC↗ |
| Bruder Scott P | Director | A Award | 2016-04-28 | 2016-04-29 | 18,692 | — | $0 | 18,692 | SEC↗ |
| Holt Matthew S. | Director, 10% Owner | A Award | 2016-04-28 | 2016-04-29 | 18,232 | — | $0 | 18,232 | SEC↗ |
| Luehring Jens | Director, 10% Owner | A Award | 2016-04-28 | 2016-04-29 | 19,860 | — | $0 | 19,860 | SEC↗ |
| Cloyd Mary Ann | Director | A Award | 2016-04-28 | 2016-04-29 | 21,858 | — | $0 | 21,858 | SEC↗ |
| Amin Naseem | Director | A Award | 2016-04-28 | 2016-04-29 | 23,365 | — | $0 | 23,365 | SEC↗ |
| Weinstein Adam | Director, 10% Owner | A Award | 2016-04-28 | 2016-04-29 | 16,767 | — | $0 | 16,767 | SEC↗ |
| Moura Andre V. | Director | A Award | 2016-04-28 | 2016-04-29 | 20,716 | — | $0 | 20,716 | SEC↗ |
| Tenenbaum Fabian | CFO & Chief Business Officer | A Award deriv | 2016-02-29 | 2016-03-01 | 130,000 | — | $0 | 130,000 | SEC↗ |
| Cloyd Mary Ann | Director | A Award deriv | 2016-02-11 | 2016-02-16 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Peacock Jonathan M | President and CEO | A Award | 2016-01-25 | 2016-01-27 | 165,975 | — | $0 | 217,702 | SEC↗ |
| Dekker Martin | VP of Device Engineering | A Award | 2016-01-19 | 2016-01-21 | 36,514 | — | $0 | 36,514 | SEC↗ |
| Edmonds Amy | VP Clinical Operations & Adm | A Award | 2016-01-19 | 2016-01-21 | 36,514 | — | $0 | 36,514 | SEC↗ |
| Quinn Deborah | Chief Medical Officer | A Award | 2016-01-19 | 2016-01-21 | 49,792 | — | $0 | 49,792 | SEC↗ |
| Fernandes Peter | Chief Regulatory Officer | A Award | 2016-01-19 | 2016-01-21 | 53,112 | — | $0 | 55,507 | SEC↗ |
| Peacock Jonathan M | President and CEO | P Buy | 2015-12-16 | 2015-12-17 | 12,800 | $2.76 | $35.3K | 51,727 | SEC↗ |
| Peacock Jonathan M | President and CEO | P Buy | 2015-12-15 | 2015-12-17 | 7,500 | $2.72 | $20.4K | 38,927 | SEC↗ |
| Abrams David | Treasurer | A Award | 2015-12-01 | 2015-12-03 | 13,116 | — | $0 | 13,116 | SEC↗ |
| Peacock Jonathan M | President and CEO | P Buy | 2015-08-19 | 2015-08-20 | 5,000 | $5.48 | $27.4K | 31,427 | SEC↗ |
| Agrawal Amit | Chief Operating Officer | A Award deriv | 2015-07-08 | 2015-07-13 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Amin Naseem | Director | A Award deriv | 2015-06-29 | 2015-07-01 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Peacock Jonathan M | President and CEO | P Buy | 2015-05-20 | 2015-05-22 | 5,560 | $8.69 | $48.3K | 26,427 | SEC↗ |
| MEGLASSON MARTIN | Chief Scientific Officer | P Buy | 2015-05-20 | 2015-05-22 | 712 | $8.40 | $6.0K | 19,098 | SEC↗ |
| Fernandes Peter | Chief Regulatory Officer | A Award deriv | 2015-05-18 | 2015-05-20 | 10,000 | — | $0 | 10,000 | SEC↗ |
| Bruder Scott P | Director | A Award deriv | 2015-05-12 | 2015-05-14 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Huennekens R Scott | Director | A Award deriv | 2015-05-12 | 2015-05-14 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Peacock Jonathan M | President and CEO | A Award deriv | 2015-03-12 | 2015-03-16 | 16,000 | — | $0 | 16,000 | SEC↗ |
| Peacock Jonathan M | President and CEO | A Award deriv | 2015-03-12 | 2015-03-16 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Naidu Manesh | Chief Business Officer | A Award deriv | 2015-03-12 | 2015-03-16 | 4,892 | — | $0 | 4,892 | SEC↗ |
| MEGLASSON MARTIN | Chief Scientific Officer | A Award deriv | 2015-03-12 | 2015-03-16 | 8,297 | — | $0 | 8,297 | SEC↗ |
| Heyrman Reinilde | Chief Clinical Dev. Officer | A Award deriv | 2015-03-12 | 2015-03-16 | 9,909 | — | $0 | 9,909 | SEC↗ |
| Abrams David | Treasurer | A Award deriv | 2015-03-12 | 2015-03-16 | 2,564 | — | $0 | 2,564 | SEC↗ |
| Peacock Jonathan M | President and CEO | P Buy | 2015-02-19 | 2015-02-23 | 20,800 | $12.00 | $249.6K | 20,867 | SEC↗ |
| Naidu Manesh | Chief Business Officer | P Buy | 2015-02-19 | 2015-02-23 | 1,500 | $12.00 | $18.0K | 11,319 | SEC↗ |
| MEGLASSON MARTIN | Chief Scientific Officer | P Buy | 2015-02-19 | 2015-02-23 | 12,000 | $12.00 | $144.0K | 18,386 | SEC↗ |
| Heyrman Reinilde | Chief Clinical Dev. Officer | P Buy | 2015-02-19 | 2015-02-23 | 1,500 | $12.00 | $18.0K | 9,483 | SEC↗ |
| Tasse Daniel | Director | P Buy | 2015-02-19 | 2015-02-23 | 25,000 | $12.00 | $300.0K | 128,898 | SEC↗ |
| Luehring Jens | Director, 10% Owner | P Buy | 2015-02-19 | 2015-02-23 | 358,916 | $12.00 | $4.31M | 1,629,804 | SEC↗ |
| Linde North America, Inc. | 10% Owner | P Buy | 2015-02-19 | 2015-02-23 | 358,916 | $12.00 | $4.31M | 1,629,804 | SEC↗ |
| Holt Matthew S. | Director, 10% Owner | P Buy | 2015-02-19 | 2015-02-23 | 1,070,166 | $12.00 | $12.84M | 4,859,885 | SEC↗ |
| Weinstein Adam | Director, 10% Owner | P Buy | 2015-02-19 | 2015-02-23 | 1,070,166 | $12.00 | $12.84M | 4,859,885 | SEC↗ |
| KLINSKY STEVEN B | 10% Owner | P Buy | 2015-02-19 | 2015-02-23 | 1,070,166 | $12.00 | $12.84M | 4,859,885 | SEC↗ |
| NELSEN ROBERT | Director, 10% Owner | P Buy | 2015-02-19 | 2015-02-23 | 212,666 | $12.00 | $2.55M | 965,660 | SEC↗ |
| ARCH VENTURE PARTNERS VI LLC | 10% Owner | P Buy | 2015-02-19 | 2015-02-23 | 212,666 | $12.00 | $2.55M | 965,660 | SEC↗ |
| Abrams David | Treasurer | A Award deriv | 2015-02-13 | 2015-02-19 | 1,995 | — | $0 | 1,995 | SEC↗ |
| Heyrman Reinilde | Chief Clinical Dev. Officer | A Award deriv | 2015-02-13 | 2015-02-19 | 1,995 | — | $0 | 1,995 | SEC↗ |
| Naidu Manesh | Chief Business Officer | A Award deriv | 2015-02-13 | 2015-02-19 | 1,995 | — | $0 | 1,995 | SEC↗ |
| MEGLASSON MARTIN | Chief Scientific Officer | A Award deriv | 2015-02-13 | 2015-02-19 | 1,995 | — | $0 | 1,995 | SEC↗ |
| Holt Matthew S. | Director, 10% Owner | D To issuer | 2015-02-12 | 2015-02-23 | 460,144 | — | $0 | 3,329,575 | SEC↗ |
| Holt Matthew S. | Director, 10% Owner | A Award | 2015-02-12 | 2015-02-23 | 460,144 | — | $0 | 3,789,719 | SEC↗ |
| Weinstein Adam | Director, 10% Owner | A Award | 2015-02-12 | 2015-02-23 | 460,144 | — | $0 | 3,789,719 | SEC↗ |
| Weinstein Adam | Director, 10% Owner | D To issuer | 2015-02-12 | 2015-02-23 | 460,144 | — | $0 | 3,329,575 | SEC↗ |
| NELSEN ROBERT | Director, 10% Owner | A Award | 2015-02-12 | 2015-02-23 | 752,994 | — | $0 | 752,994 | SEC↗ |